FIRST AMENDMENT TO
LICENSE AGREEMENT NO. A13169
WHEREAS, the University of Florida Research Foundation, Inc., a not-for-profit corporation duly organized and existing under the laws of the State of Florida and having its principal office at 223 Grinter Hall, Gainesville, Florida 32611 U.S.A. (hereinafter referred to as UFRF), and Audentes Therapeutics, Inc., a corporation duly organized under the laws of the State of Delaware, and having its principal office at 101 Montgomery Street, Suite 2650, San Francisco, CA, 94104, (hereinafter referred to as Licensee) entered into a License Agreement effective July 28, 2015 (hereinafter License Agreement);
WHEREAS, the parties now wish to amend the License Agreement;
NOW THEREFORE, in consideration of the premises and mutual covenants contained herein the parties hereto agree as follows;
1. The following section of the license agreement shall be re-written to read as follows:
Appendix E - Milestones
|File an investigational new drug application IND or similar in any country||October 31, 2016|
|First Dosing in Phase I or II clinical trial or similar in any country||March 31, 2017|
|First Dosing in Phase III clinical trial or similar in any country||December 31, 2019|
|First filing of a License Application in any country||December 31, 2023|
2. All other provisions of the License Agreement shall remain in full force and effect and unmodified by this Amendment.
3. This amendment shall be effective April 27, 2016 and shall be referred to as the First Amendment.
|UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.||AUDENTES THERAPEUTICS, INC.|
|Name:||David L. Day||Name:||Natalie Holles|
|Title:||Director of Technology Licensing||Title:||SVP and Chief Operating Officer|